Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.
about
Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection MethodsImpact of the New Delhi metallo-beta-lactamase on beta-lactam antibioticsEvaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill ExperimentsClinical and laboratory considerations for the rapid detection of carbapenem-resistant Enterobacteriaceae.Carbapenemase-producing Klebsiella pneumoniae.A Review of Novel Combinations of Colistin and Lipopeptide or Glycopeptide Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii.In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae.In vitro and in vivo analysis of antimicrobial agents alone and in combination against multi-drug resistant Acinetobacter baumannii.Carbapenemase-producing Enterobacteriaceae.Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial DominanceSynergistic killing of NDM-producing MDR Klebsiella pneumoniae by two 'old' antibiotics-polymyxin B and chloramphenicol.Optimizing Polymyxin Combinations Against Resistant Gram-Negative BacteriaFosfomycinFosfomycin: Resurgence of an old companion.Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.Synergistic combinations of polymyxins.Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii.Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria.Management of Intra-abdominal Infections due to Carbapenemase-Producing Organisms.Treatment option for sepsis in children in the era of antibiotic resistance.A review of the pharmacokinetics and pharmacodynamics of aztreonam.Colistin: still a lifesaver for the 21st century?Recent advances and perspectives in the design and development of polymyxins.Clinical Pharmacokinetics and Pharmacodynamics of Colistin.Tigecycline: Alone or in combination?Synergistic activity profile of an antimicrobial peptide against multidrug-resistant and extensively drug-resistant strains of Gram-negative bacterial pathogens.New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae.Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae.Emergence of Carbapenem-Resistant Klebsiella pneumoniae: Progressive Spread and Four-Year Period of Observation in a Cardiac Surgery Division.Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii?Combination Therapy against Polymicrobial Infection, Including by NDM-1-Producing Enterobacteriaceae Resistant to Colistin.Were all carbapenemases created equal? Treatment of NDM-producing extensively drug-resistant Enterobacteriaceae: a case report and literature review.Screening for synergistic activity of antimicrobial combinations against carbapenem-resistant Enterobacteriaceae using inkjet printer-based technology."Double carbapenem" and oral fosfomycin for the treatment of complicated urinary tract infections caused by blaNDM -harboring Enterobacteriaceae in kidney transplantation.Combination therapy for extensively-drug resistant gram-negative bacteria.Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae.Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.In vitro antibacterial effect of fosfomycin combination therapy against colistin-resistant Klebsiella pneumoniae.Synergistic Activity of Colistin/Fosfomycin Combination against Carbapenemase-Producing Klebsiella pneumoniae in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
P2860
Q26744583-DC2D222D-BB7A-45E9-BA55-0B1CEFB8B37CQ26783267-7D27B63E-DB29-439E-855A-AEE0E595D41FQ28550910-DD7AA1DA-9BB2-4830-AF47-2EE47498557EQ33816207-52DC43EA-762D-4143-9231-077459CFF68CQ34201937-A15EE3C5-4E5F-4B82-800A-43FEF051FBEEQ34726120-9CF064CA-A074-431B-AB84-4E327A53CC91Q35385713-8545405A-6938-4540-A49F-CDD5AD410DDAQ35650658-1D4BF952-AA0A-4DF2-8398-6D724FEBF824Q35751615-D51648A4-286C-428D-85C8-645AC2954FB6Q36076066-B550C6A7-4FFE-4D75-BCA0-EE9BAFE414CAQ36255587-EBD6C42E-7C8B-4273-9C22-745CD013C18EQ36363261-83D22220-5354-4C02-A63C-D0836B123867Q36675246-2072CA2A-1778-43B9-A394-95D44747A66CQ36803694-3EE6EE6B-D66C-43DE-8DD1-FBEC213880EFQ37562099-756A67EA-C596-4576-A021-D8B01F9878D2Q37586960-E5B97D41-485D-4491-8C9C-D92AEE993866Q37586963-73E9D11C-09D7-4987-91A1-C73B44335E5BQ38199180-1A5A9BB7-52A3-4F50-B925-208B7A082420Q38240411-C75535BF-1F4F-456D-A2D1-B94CFBC966EEQ38246118-0D18632E-DFB3-483E-B4C3-1BC35EF6686CQ38873850-6F9350AC-1F5C-4122-A8D4-7838D98C87F5Q38940249-72B2EC75-F243-433E-A711-E57AD271D249Q39190865-10361134-44BB-4BAB-B163-D5C6397C1F2AQ39333751-26334FFC-106B-47E3-B423-F6196B67B9DCQ39916184-3506B9C7-E915-4094-BB1D-435969CC9890Q40340725-A8C8227C-581C-4EF1-ADBC-F57CCF4B1AF3Q40342720-28243252-D9F4-4C6E-993F-26EF62912366Q40441668-A5265F8E-D496-412C-AD38-B4A49A382B8CQ40745160-DEDE162A-3D33-40B8-8EE7-2DF80E870990Q41110741-F50135BA-2970-401E-9C23-2C4123AC4732Q42349300-CFF87C89-6D38-4012-8437-73FF5B848A54Q46152898-205146A9-4512-4FFD-8983-351564E4BAF2Q47677580-A2FC6DBF-C6CF-433B-AE1C-63C35EAFA8EEQ47730399-B4043DAB-BBF2-49C2-BC77-346275E74F66Q47819621-CE68686C-DBC3-41BA-8E42-CA01E2BCC436Q49196415-A29BA082-8445-433D-B341-B8C4DB62C944Q50053159-32D3A232-5099-4658-8FD8-B190DE8CF14AQ52695014-6AB1BE84-37C5-4D20-81A8-14052C6CB39BQ55071894-6D9E5E21-C15C-41F9-B098-AA6463BF4551Q55340900-328BF3B3-03A8-43E9-8693-7F5DFF1EACF0
P2860
Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evaluation of double- and trip ...... n vitro time-kill experiments.
@en
Evaluation of double- and trip ...... n vitro time-kill experiments.
@nl
type
label
Evaluation of double- and trip ...... n vitro time-kill experiments.
@en
Evaluation of double- and trip ...... n vitro time-kill experiments.
@nl
prefLabel
Evaluation of double- and trip ...... n vitro time-kill experiments.
@en
Evaluation of double- and trip ...... n vitro time-kill experiments.
@nl
P2093
P2860
P356
P1476
Evaluation of double- and trip ...... in vitro time-kill experiments
@en
P2093
P2860
P304
P356
10.1128/AAC.00741-13
P407
P50
P577
2014-01-06T00:00:00Z